CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
hormone replacement therapy +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000611
NCT00000611Phase 3Completed

Women's Health Initiative (WHI)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Apr 15, 2016

In Brief

A Phase 3 clinical trial evaluating hormone replacement therapy, estrogens, and 6 other interventions for Bone Diseases and 8 related conditions. Completed.

Detailed Summary

To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).

Study Details

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

hormone replacement therapydrug

estrogensdrug

progestinsdrug

estrogen replacement therapydrug

diet, fat-restrictedbehavioral

calciumdrug

vitamin Ddrug

dietary supplementsbehavioral